Latest News

The FDA approved the Supplemental New Drug Application for phentolamine 0.75% (Ryzumvi, Opus Genetics/Viatris) to treat presbyopia.

Eye care providers urged FDA advisers to approve SYD-101, citing myopia’s lifelong risks, compounding gaps and STAR trial results.

Lambert-Eaton myasthenic syndrome is a rare autoimmune disorder of the neuromuscular junction that should be differentiated from myasthenia gravis, another neuromuscular junction disorder.

Luma, an eye-tracking and assessment tool, helps eye care professionals gain objective insights into visual performance.

Johnson & Johnson spotlights contrast-driven cataract outcomes at AAO 2026, touting TECNIS PureSee/Odyssey data, 1M implants, and SmartLOAD injector sustainability.

Arun C. Gulani, MD, applies his keratoconus classification to cross-linking, rings, transplant, lens surgery, and staged care.

Rheumatoid arthritis, is an autoimmune disorder, develops more often in women than men in a 3:1 ratio.

Sarah Cheng, MD, PhD, discusses findings on orbital tissue changes in thyroid eye disease after teprotumumab treatment.

In a single day, the FDA cleared the first nonprescription apraclonidine drop, the first at-home subcutaneous therapy for thyroid eye disease, and a presbyopia indication for an established pupil-modulating drop.

Eleonora Lad, MD, PhD, Dimitra Skondra, MD, PhD, and John Kitchens, MD, point to structure and function, diet and the gut, and the future of reimbursement.

Spectacle lenses with highly aspherical lenslets are safe and effective for reducing myopia progression in US children.

Enrollment in the licaminlimab trial closed above target, with two-thirds of 176 patients carrying a TNFR1 variant associated with stronger treatment response. Topline data are expected around year-end 2026.

Prevent Blindness marks IED Week, October 19 to 25, as new therapies and pivotal trials reshape care for uveitis and thyroid eye disease.